Why Is NTLA Stock Jumping 5% Premarket Today?
Intellia unveiled additional Phase 3 data for its CRISPR-based HAE treatment, Lonvo-z. In the Haelo trial, Lonvo-z reduced attacks requiring rescue medication by 89%. Patients also reported significant quality-of-life improvements, with scores improving by more than 17 points compared with placebo. Intellia has already begun its FDA filing and is targeting a first-half 2027 launch. … Read more